Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 8, 2025
Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025
Read more at globenewswire.comNASDAQ:CGEM (11/14/2025, 11:35:48 AM)
8.6
+0.33 (+3.99%)
Find more stocks in the Stock Screener
CGEM Latest News and Analysis
